X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.biopharmadive.com/news/bristol-myers-layoffs-restructuring-cost-savings/714254/
https://www.investor.jnj.com/files/doc_news/2024/Apr/22/carvykti_cartitude-4_ec-release_final.pdf
https://www.prnewswire.com/news-releases/iaso-bio-announces-nmpas-ind-approval-for-equecabtagene-autoleucel-in-second--and-third-line-treatment-of-multiple-myeloma-302103455.html
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-overall-survival-phase-3-trial
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217265
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213405
https://www.fiercepharma.com/pharma/bristol-myers-slashes-revlimid-sales-projection-1b-now-sees-overall-revenue-decline-2023
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212414
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215759
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215759
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-pharma-launches-additional-strengths-of-generic-version-of-revlimid-in-us/articleshow/98538080.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213885
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211846
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210480
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210154
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201452
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-gets-usfda-nod-to-market-generic-medication/articleshow/97795222.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://endpts.com/bristol-myers-turns-attention-to-new-products-in-wake-of-revlimid-patent-loss/
https://health.economictimes.indiatimes.com/news/pharma/claims-against-dr-reddys-over-revlimid-in-us-dismissed/96590198
https://www.biospace.com/article/releases/innocare-announces-approval-of-tafasitamab-in-combination-with-lenalidomide-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-hong-kong/?s=95
https://www.clinicaltrialsarena.com/news/china-cde-innocare-nhl-therapy/
https://www.digitaljournal.com/pr/alfa-chemistry-enriches-api-supply-by-adding-lenalidomide-parecoxib-sodium-and-rivaroxaban
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213912
https://www.globenewswire.com//news-release/2022/12/12/2571773/0/en/Starton-Therapeutics-STAR-LLD-Continuous-Delivery-Shows-Superior-Tumor-Reduction-and-Progression-Free-Survival-PFS-Compared-to-Pulsatile-Lenalidomide-Treatment-in-Lenalidomide-Resi.html
https://www.prnewswire.com/news-releases/janssen-presents-efficacy-and-subgroup-analyses-from-maia-study-showing-long-term-results-of-darzalex-daratumumab-based-regimen-in-newly-diagnosed-transplant-ineligible-multiple-myeloma-301700443.html
https://www.prnewswire.com/news-releases/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma-301699753.html
https://health.economictimes.indiatimes.com/news/pharma/dr-reddys-laboratories-sees-generic-revlimid-other-launches-to-keep-us-business-firing/95153981
https://www.fiercepharma.com/pharma/even-revlimids-star-fades-bristol-myers-squibbs-quartet-therapeutic-areas-operating-critical
https://pink.pharmaintelligence.informa.com/PS147023/Pharma-Readies-For-Price-Caps-On-Glargine-Teneligliptin-Lenalidomide-In-India
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210154
https://www.biospace.com/article/releases/dr-reddy-s-laboratories-announces-the-launch-of-lenalidomide-capsules-in-the-u-s-with-two-of-six-strengths-eligible-for-first-to-market-180-day-exclusivity/
https://www.expresspharma.in/cipla-gets-us-fda-nod-for-cancer-drug/
https://www.bizzbuzz.news/industry/pharma/cipla-gets-usfda-approval-for-cancer-drug-1165526
https://www.prnewswire.com/news-releases/cipla-receives-usfda-approval-for-generic-version-of-revlimid-lenalidomide-capsules-301619212.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209348
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211022
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213912
https://www.clinicaltrialsarena.com/news/janssen-trial-multiple-myeloma/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-gearing-up-to-get-substantial-slice-of-revlimid-generic-opportunity-in-us/articleshow/93313847.cms
https://www.globenewswire.com/news-release/2022/07/13/2479358/0/en/Starton-Therapeutics-Reports-Positive-Results-from-Phase-1-Study-Evaluating-STAR-LLD-Continuous-Delivery-Lenalidomide.html
https://www.fdanews.com/articles/208547-bms-settles-patent-dispute-with-alembic-over-blockbuster-revlimid?v=preview
https://scrip.pharmaintelligence.informa.com/SC146441/Zydus-Pivots-To-Multivariant-COVID19-Vaccine-Looks-To-Revlimid-Opportunity
https://www.fiercepharma.com/pharma/sales-bristol-myers-revlimid-are-eroding-faster-expected-company-adjusts-projections
Market Place
Share 
